ClinicalTrials.gg
TerminatedNCT03559270BREEZE-AD6Updated Nov 8, 2022Results posted

A Study of Baricitinib (LY3009104) in Participants With Moderate to Severe Atopic Dermatitis

A Phase 3 interventional study of Baricitinib in Atopic Dermatitis, sponsored by Eli Lilly and Company. Terminated at 74 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-11-08.

Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Treatment

Why this study was terminated
Terminated due to lack of alignment during regulatory negotiations.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
374
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies testing baricitinib in Dermatitis, Atopic — 1 open to participants now, 1 under way, none of them phase 3. baricitinib · Dermatitis, Atopic.

Enrollment
7th of 11
374 · median 440
Started
2018
with 4 others
Phase 3
8 of 11
none open now
Registered
7th of 11
by date
Lead sponsor
9 of 11
Eli Lilly and Company

Among the 11 studies testing baricitinib in Dermatitis, Atopic, this one is the 7th largest by enrollment, is one of 5 that started in 2018, is one of 8 in phase 3, and was the 7th registered.

Dermatitis, Atopic

1,594 studies on the registry are indexed under Dermatitis, Atopic; 287 are open to participants now.

Browse Dermatitis, Atopic studies →

Open to participants now

1 of the 11 studies testing baricitinib in Dermatitis, Atopic is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About baricitinib

baricitinib: first FDA approval 2018 (OLUMIANT), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 194 Dermatitis, Atopic studies recruiting now, 83 (43%) set no upper age limit and 95 (49%) stop at 75 or younger; 94 take children under 18; 51 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies testing baricitinib in Dermatitis, Atopic, or all of them as a file.
02

Study summary

This open-label study will evaluate the long-term efficacy and safety of baricitinib in adult participants with moderate to severe atopic dermatitis (AD).

03

Conditions studied

  • Atopic Dermatitis

Keywords

  • eczema
  • atopic eczema
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Have participated in Study JAIW (NCT03435081), and meet specific completion requirements for that study, and do not meet any of the following Exclusions:

  • Have significant uncontrolled cerebro-cardiovascular (e.g., myocardial infarction [MI], unstable angina, unstable arterial hypertension, severe heart failure, or cerebrovascular accident), respiratory, hepatic, renal, gastrointestinal, endocrine, hematologic, neuropsychiatric disorders, or abnormal laboratory values that developed during a previous baricitinib study that, in the opinion of the investigator, pose an unacceptable risk to the participant if product continues to be administered.
  • Have a known to baricitinib or any component of this investigational product.
  • Had investigational product permanently discontinued at any time during a previous baricitinib study, except for participants who had investigational product discontinued during originating study because of rescue with an oral systemic AD therapy (e.g., , cyclosporine, methotrexate).
  • Had temporary investigational product interruption continue at the final study visit of a previous baricitinib study and, in the opinion of the investigator, this poses an unacceptable risk for the participant's participation in the study.
  • Pregnant or breastfeeding

OR

  • Have not participated in a Study JAIW (NCT03435081) and satisfy the following criteria:

Inclusion criteria

Inclusion Criteria:

  • Have a diagnosis of atopic dermatitis (AD) at least 12 months before screening.
  • Have moderate to severe AD, including all of the following:

    • EASI score ≥16
    • IGA score of ≥3
    • 10%- 50% BSA involvement
  • Have had inadequate response or intolerance to existing topical (applied to the skin) medications within 6 months preceding screening.
  • Are willing to discontinue certain treatments for eczema (such as systemic and topical treatments)
  • Agree to use emollients daily.

Exclusion criteria

Exclusion Criteria:

  • Are currently experiencing or have a history of other concomitant skin conditions (e.g., psoriasis or lupus erythematosus), or a history of erythrodermic, , or unstable skin disease that requires frequent hospitalizations and/or intravenous treatment for skin infections.
  • A history of eczema herpeticum within 12 months, and/or a history of 2 or more episodes of eczema herpeticum in the past.
  • Participants who are currently experiencing a skin infection that requires treatment, or is currently being treated, with topical or systemic antibiotics.
  • Have any serious illness that is anticipated to require the use of systemic or otherwise interfere with study participation or require active frequent monitoring (e.g., unstable chronic asthma).
  • Have been treated with the following therapies:

    • monoclonal antibody for less than 5 half-lives before randomization
    • received prior treatment with any oral Janus kinase (JAK) inhibitor less than 4 weeks before randomization
    • received any parenteral corticosteroid administered by intramuscular or intravenous injection within 6 weeks of planned randomization or are anticipated to require parenteral injection of corticosteroids during the study
    • have had an intra-articular corticosteroid injection within 6 weeks of planned randomization
    • probenecid at the time of randomization that cannot be discontinued for the duration of the study
  • Have high blood pressure characterized by a repeated systolic blood pressure >160 millimeters of mercury (mm Hg) or diastolic blood pressure >100 mm Hg.
  • Have had major surgery within the past eight weeks or are planning major surgery during the study.
  • Have experienced any of the following within 12 weeks of screening: myocardial infarction (MI), unstable ischemic heart disease, stroke, or Stage III/IV heart failure.
  • Have a history of venous thromboembolic event (VTE), or are considered at high risk for VTE.
  • Have a history or presence of cardiovascular, respiratory, hepatic, gastrointestinal, endocrine, hematological, neurological, lymphoproliferative disease or neuropsychiatric disorders or any other serious and/or unstable illness.
  • Have a current or recent clinically serious viral, bacterial, fungal, or parasitic infection including herpes zoster, tuberculosis.
  • Have specific laboratory abnormalities.
  • Have received certain treatments that are .
  • Pregnant or breastfeeding.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
374 participants (actual)

Study arms

  • Experimental
    Placebo/Baricitinib 2-milligram (mg)

    Open-label 2 mg baricitinib administered orally once daily (QD) to participants who randomized to placebo in the originating study (JAIW).

    Drug: Baricitinib

  • Experimental
    Baricitinib 1-mg/Baricitinib 2-mg

    Open-label 2 mg baricitinib administered orally QD to participants who randomized to 1 mg baricitinib in the originating study (JAIW).

    Drug: Baricitinib

  • Experimental
    Baricitinib 2-mg/Baricitinib 2-mg

    Open-label 2 mg baricitinib administered orally QD to participants who randomized to 2 mg baricitinib in the originating study (JAIW).

    Drug: Baricitinib

  • Experimental
    Baricitinib 2-mg Open-Label Addendum

    Participants were directly enrolled to receive open-label 2 mg baricitinib orally QD.

    Drug: Baricitinib

Interventions

  • Administered orally

    Also known as: LY3009104

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Achieving Eczema Area and Severity Index 75 (EASI75)

    The EASI assesses objective physician estimates of 2 dimensions of atopic dermatitis - disease extent and clinical signs affected: 0 = 0%; 1 = 1-9%; 2 = 10-29%; 3 = 30-49%; 4 = 50-69%; 5 = 70-89%; 6 = 90-100% and the severity of 4 clinical signs: (1) erythema, (2) edema/papulation, (3) excoriation, and (4) lichenification each on a scale of 0 to 3 (0 = none, absent; 1 = mild; 2 = moderate; 3 = severe) at 4 body sites (head/neck, trunk, upper limbs, and lower limbs). Half scores are allowed between severities 1, 2, and 3. The final EASI score was obtained by weight-averaging these 4 scores and will range from 0 to 72 (severe). The EASI75 is defined as a ≥ 75% improvement from baseline in the EASI score. The results were analyzed using non-responder imputation (NRI). All participants who either discontinued the study treatment or discontinued the study for any reason at any time were defined as non-responders for the NRI analysis for categorical variables such as EASI75.

    Time frame: Week 16

Secondary outcomes

  1. Percentage of Participants Achieving Investigator's Global Assessment (IGA) of 0 or 1

    The IGA measures the investigator's global assessment of the participant's overall severity of their atopic dermatitis (AD), based on a static, numeric 5-point scale from 0 (clear skin) to 4 (severe disease). The score is based on an overall assessment of the degree of erythema, papulation/induration, oozing/crusting, and lichenification. The results were analyzed using NRI. All participants who either discontinued the study treatment or discontinued the study for any reason at any time were defined as non-responders for the NRI analysis for categorical variables such as IGA 0/1.

    Time frame: Week 16

  2. Percentage of Participants Achieving a Body Surface Area (BSA) of ≤3%

    The BSA affected by AD will be assessed for 4 separate body regions: head and neck, trunk (including genital region), upper extremities, and lower extremities (including the buttocks). Each body region will be assessed for disease extent ranging from 0% to 100% involvement. BSA was calculated using the participant's palm using the 1% rule, 1 palm was equivalent to 1% with estimates of the number of palms it takes to cover the affected AD area. Maximum number of palms were 10 palms for head and neck (10%), 20 palms for upper extremities (20%), 30 palms for trunk, including axilla and groin (30%), 40 palms for lower extremities, including buttocks (40%). Percent of BSA for a body region was calculated as = total number of palms in a body region \* % surface area equivalent to 1 palm. Overall percent BSA of all 4 body regions ranges from 0% to 100 % with higher values representing greater severity of AD.

    Time frame: Week 16

  3. Percentage of Participants Achieving a ≥4-Point Improvement in Itch Numeric Rating Scale (NRS)

    The NRS is a participant-administered, 11-point horizontal scale anchored at 0 and 10, with 0 representing "no itch" and 10 representing "worst itch imaginable." Overall severity of a participant's itching is indicated by selecting the number, using a daily diary, that best describes the worst level of itching in the past 24 hours.

    Time frame: Week 16

07

Results

Posted Nov 8, 2022
Limitations and caveats
The trial was terminated before completion, due to lack of alignment during regulatory negotiations.

Participant flow

Eligible participants (nonresponder/partial responder: completed at least 16 weeks of treatment; responder: completed the full treatment period) from originating study JAIW (NCT03435081) enrolled into Open-label Treatment Period of JAIX \[lasting from Week 0 (baseline through Week 200) or early termination visit\]. Participants enrolled directly into Protocol Addendum I4V-MC-JAIX (2) without first completing at least 16 weeks of treatment in originating study JAIW.

Participant flow — Overall Study
MilestonePlacebo/Baricitinib 2-milligram (mg)Baricitinib 1-mg/Baricitinib 2-mgBaricitinib 2-mg/Baricitinib 2-mgBaricitinib 2-mg Open-Label Addendum
Started11711910830
Received at least one dose of study drug11711910830
Completed0100
Not completed11711810830
Withdrew: Adverse event6530
Withdrew: Lack of efficacy3452372
Withdrew: Death0200
Withdrew: Lost to follow-up164123
Withdrew: Sponsor decision38313518
Withdrew: Withdrawal by subject1921187
Withdrew: Physician decision3210
Withdrew: Pregnancy0100
Withdrew: Protocol violation1020

Outcome measures

PrimaryPercentage of Participants Achieving Eczema Area and Severity Index 75 (EASI75)

The EASI assesses objective physician estimates of 2 dimensions of atopic dermatitis - disease extent and clinical signs affected: 0 = 0%; 1 = 1-9%; 2 = 10-29%; 3 = 30-49%; 4 = 50-69%; 5 = 70-89%; 6 = 90-100% and the severity of 4 clinical signs: (1) erythema, (2) edema/papulation, (3) excoriation, and (4) lichenification each on a scale of 0 to 3 (0 = none, absent; 1 = mild; 2 = moderate; 3 = severe) at 4 body sites (head/neck, trunk, upper limbs, and lower limbs). Half scores are allowed between severities 1, 2, and 3. The final EASI score was obtained by weight-averaging these 4 scores and will range from 0 to 72 (severe). The EASI75 is defined as a ≥ 75% improvement from baseline in the EASI score. The results were analyzed using non-responder imputation (NRI). All participants who either discontinued the study treatment or discontinued the study for any reason at any time were defined as non-responders for the NRI analysis for categorical variables such as EASI75.

Time frame:
Week 16
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Eczema Area and Severity Index 75 (EASI75)
percentage of participantsPlacebo/Baricitinib 2-mgBaricitinib 1-mg/Baricitinib 2-mgBaricitinib 2-mg/Baricitinib 2-mgBaricitinib 2-mg Open-Label Addendum
Percentage of Participants Achieving Eczema Area and Severity Index 75 (EASI75)59.040.345.450.0
SecondaryPercentage of Participants Achieving Investigator's Global Assessment (IGA) of 0 or 1

The IGA measures the investigator's global assessment of the participant's overall severity of their atopic dermatitis (AD), based on a static, numeric 5-point scale from 0 (clear skin) to 4 (severe disease). The score is based on an overall assessment of the degree of erythema, papulation/induration, oozing/crusting, and lichenification. The results were analyzed using NRI. All participants who either discontinued the study treatment or discontinued the study for any reason at any time were defined as non-responders for the NRI analysis for categorical variables such as IGA 0/1.

Time frame:
Week 16
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Investigator's Global Assessment (IGA) of 0 or 1
percentage of participantsPlacebo/Baricitinib 2-mgBaricitinib 1-mg/Baricitinib 2-mgBaricitinib 2-mg/Baricitinib 2-mgBaricitinib 2-mg Open-Label Addendum
Percentage of Participants Achieving Investigator's Global Assessment (IGA) of 0 or 144.418.529.640.0
SecondaryPercentage of Participants Achieving a Body Surface Area (BSA) of ≤3%

The BSA affected by AD will be assessed for 4 separate body regions: head and neck, trunk (including genital region), upper extremities, and lower extremities (including the buttocks). Each body region will be assessed for disease extent ranging from 0% to 100% involvement. BSA was calculated using the participant's palm using the 1% rule, 1 palm was equivalent to 1% with estimates of the number of palms it takes to cover the affected AD area. Maximum number of palms were 10 palms for head and neck (10%), 20 palms for upper extremities (20%), 30 palms for trunk, including axilla and groin (30%), 40 palms for lower extremities, including buttocks (40%). Percent of BSA for a body region was calculated as = total number of palms in a body region \* % surface area equivalent to 1 palm. Overall percent BSA of all 4 body regions ranges from 0% to 100 % with higher values representing greater severity of AD.

Time frame:
Week 16
Reported as:
Number · percentage of participants
Percentage of Participants Achieving a Body Surface Area (BSA) of ≤3%
percentage of participantsPlacebo/Baricitinib 2-mgBaricitinib 1-mg/Baricitinib 2-mgBaricitinib 2-mg/Baricitinib 2-mgBaricitinib 2-mg Open-Label Addendum
Percentage of Participants Achieving a Body Surface Area (BSA) of ≤3%39.321.835.243.3
SecondaryPercentage of Participants Achieving a ≥4-Point Improvement in Itch Numeric Rating Scale (NRS)

The NRS is a participant-administered, 11-point horizontal scale anchored at 0 and 10, with 0 representing "no itch" and 10 representing "worst itch imaginable." Overall severity of a participant's itching is indicated by selecting the number, using a daily diary, that best describes the worst level of itching in the past 24 hours.

Time frame:
Week 16
Reported as:
Number · percentage of participants
Percentage of Participants Achieving a ≥4-Point Improvement in Itch Numeric Rating Scale (NRS)
percentage of participantsPlacebo/Baricitinib 2-mgBaricitinib 1-mg/Baricitinib 2-mgBaricitinib 2-mg/Baricitinib 2-mgBaricitinib 2-mg Open-Label Addendum
Percentage of Participants Achieving a ≥4-Point Improvement in Itch Numeric Rating Scale (NRS)41.929.430.626.7

Adverse events

Collected over Baseline to Follow-up (Up to 204 Weeks). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo/Baricitinib 2-mg0/117 (0%)8/117 (6.8%)35/117 (29.9%)
Baricitinib 1-mg/Baricitinib 2-mg2/119 (1.7%)8/119 (6.7%)22/119 (18.5%)
Baricitinib 2-mg/Baricitinib 2-mg0/108 (0%)10/108 (9.3%)28/108 (25.9%)
Baricitinib 2-mg Open-Label Addendum0/29 (0%)0/29 (0%)2/29 (6.9%)
Most frequent serious events
Showing 10 of 34
Most frequent serious events
EventPlacebo/Baricitinib 2-mgBaricitinib 1-mg/Baricitinib 2-mgBaricitinib 2-mg/Baricitinib 2-mgBaricitinib 2-mg Open-Label Addendum
Myocardial infarctionCardiac disorders0/1172/1190/1080/29
LymphadenopathyBlood and lymphatic system disorders0/1170/1191/1080/29
CellulitisInfections and infestations0/1171/1191/1080/29
Graft infectionInfections and infestations0/1170/1191/1080/29
Pneumonia aspirationInfections and infestations0/1170/1191/1080/29
Streptococcal abscessInfections and infestations0/1170/1191/1080/29
Wound infectionInfections and infestations0/1170/1191/1080/29
Injury cornealInjury, poisoning and procedural complications0/1170/1191/1080/29
Vascular graft thrombosisInjury, poisoning and procedural complications0/1170/1191/1080/29
Cutaneous t-cell lymphoma stage ivNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/1170/1191/1080/29
Most frequent other events
Most frequent other events
EventPlacebo/Baricitinib 2-mgBaricitinib 1-mg/Baricitinib 2-mgBaricitinib 2-mg/Baricitinib 2-mgBaricitinib 2-mg Open-Label Addendum
Upper respiratory tract infectionInfections and infestations12/1178/11911/1080/29
NasopharyngitisInfections and infestations10/1179/1197/1080/29
Covid-19Infections and infestations9/1173/1195/1081/29
HeadacheNervous system disorders8/1170/1191/1080/29
Urinary tract infectionInfections and infestations7/1176/1197/1081/29
AcneSkin and subcutaneous tissue disorders6/1171/1191/1080/29

Baseline characteristics

Modified intent-to-treat (mITT) population included all participants who received at least one dose of study drug.

Age, Continuous
Age, Continuous(years)Placebo/Baricitinib 2-mgBaricitinib 1-mg/Baricitinib 2-mgBaricitinib 2-mg/Baricitinib 2-mgBaricitinib 2-mg Open-Label AddendumTotal
Mean39.90 ± 16.8740.70 ± 16.8639.30 ± 15.0543.80 ± 17.6740.30 ± 16.41
Sex: Female, Male
Sex: Female, Male(Participants)Placebo/Baricitinib 2-mgBaricitinib 1-mg/Baricitinib 2-mgBaricitinib 2-mg/Baricitinib 2-mgBaricitinib 2-mg Open-Label AddendumTotal
Female55605716188
Male62595114186
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Placebo/Baricitinib 2-mgBaricitinib 1-mg/Baricitinib 2-mgBaricitinib 2-mg/Baricitinib 2-mgBaricitinib 2-mg Open-Label AddendumTotal
Hispanic or Latino1713191059
Not Hispanic or Latino971058720309
Unknown or Not Reported31206
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Placebo/Baricitinib 2-mgBaricitinib 1-mg/Baricitinib 2-mgBaricitinib 2-mg/Baricitinib 2-mgBaricitinib 2-mg Open-Label AddendumTotal
American Indian or Alaska Native22206
Asian272419474
Native Hawaiian or Other Pacific Islander00101
Black or African American201522461
White61726022215
More than one race654015
Unknown or Not Reported11002
Region of Enrollment
Region of Enrollment(participants)Placebo/Baricitinib 2-mgBaricitinib 1-mg/Baricitinib 2-mgBaricitinib 2-mg/Baricitinib 2-mgBaricitinib 2-mg Open-Label AddendumTotal
Canada3638310105
United States81817730269
08

Study locations

74 sites
  • University of Alabama at Birmingham
    Birmingham, Alabama 35233, United States
  • Johnson Dermatology
    Fort Smith, Arkansas 72916, United States
  • California Dermatology & Clinical Research Institute
    Encinitas, California 92024, United States
  • First OC Dermatology
    Fountain Valley, California 92708, United States
  • Center For Dermatology Clinical Research, Inc.
    Fremont, California 94538, United States
  • Keck School of Medicine University of Southern California
    Los Angeles, California 90033, United States
  • Wallace Medical Group, Inc.
    Los Angeles, California 90056, United States
  • University of California Davis-Dermatology
    Sacramento, California 95816, United States
  • Medical Center For Clinical Research
    San Diego, California 92108, United States
  • University Clinical Trials, Inc.
    San Diego, California 92123, United States
  • Southern California Dermatology, Inc.
    Santa Ana, California 92701, United States
  • Clinical Science Institute
    Santa Monica, California 90404, United States
  • Care Access Research-Walnut Creek
    Walnut Creek, California 94598, United States
  • GWU/Medical Faculty Associates
    Washington, District of Columbia 20037, United States
  • Solutions Through Advanced Research, Inc.
    Jacksonville, Florida 32256, United States
  • Olympian Clinical Research
    Largo, Florida 33770, United States
  • Miami Dermatology and Laser Research
    Miami, Florida 33173, United States
  • Riverchase Dermatology and Cosmetic Surgery
    Pembroke Pines, Florida 33028, United States
  • University of South Florida
    Tampa, Florida 33612, United States
  • ForCare Clinical Research
    Tampa, Florida 33613-1244, United States
  • Dermatologic Surgery Specialists, PC
    Macon, Georgia 31217, United States
  • Advanced Medical Research
    Sandy Springs, Georgia 30328, United States
  • Advanced Clinical Research LLC
    Meridian, Idaho 83642, United States
  • Northwestern University
    Chicago, Illinois 60611, United States
  • University Dermatology
    Darien, Illinois 60561, United States
  • Arlington Dermatology
    Rolling Meadows, Illinois 60008, United States
  • Dawes Fretzin Clinical Research Group, LLC
    Indianapolis, Indiana 46250, United States
  • The Indiana Clinical Trials Center
    Plainfield, Indiana 46168, United States
  • The South Bend Clinic Center for Research
    South Bend, Indiana 46617, United States
  • Forefront Research
    Louisville, Kentucky 40241, United States
  • Dermatology and Skin Cancer Specialists
    Rockville, Maryland 20850, United States
  • Tufts Medical Center
    Boston, Massachusetts 02111, United States
  • Brigham and Women's Hospital
    Boston, Massachusetts 02115, United States
  • Great Lakes Research Group, Inc.
    Bay City, Michigan 48706, United States
  • Central Dermatology PC
    Saint Louis, Missouri 63117, United States
  • Skin Specialists, P.C
    Omaha, Nebraska 68144, United States
  • Icahn Sch of Med at Mt. Sinai
    New York, New York 10003, United States
  • DermResearchCenter of New York, Inc
    Stony Brook, New York 11790, United States
  • Bexley Dermatology Research
    Bexley, Ohio 43209, United States
  • University Hospitals Cleveland Medical Center
    Cleveland, Ohio 44106, United States
  • Wright State Univ School of Medicine
    Fairborn, Ohio 45324, United States
  • Oregon Dermatology and Research Center
    Portland, Oregon 97210, United States
  • OHSU Center for Health and Healing
    Portland, Oregon 97239, United States
  • The Pennsylvania Centre for Dermatology, LLC
    Exton, Pennsylvania 19341, United States
  • Clinical Partners, LLC
    Johnston, Rhode Island 02919, United States
  • Clinical Research Center of the Carolinas
    Charleston, South Carolina 29407, United States
  • Medical University of South Carolina
    Charleston, South Carolina 29425, United States
  • Bellaire Dermatology
    Bellaire, Texas 77401, United States
  • Modern Research Associates
    Dallas, Texas 75231, United States
  • Austin Institute for Clinical Research
    Pflugerville, Texas 78660, United States
  • Texas Dermatology and Laser Specialists
    San Antonio, Texas 78218, United States
  • University of Utah MidValley Dematology
    Murray, Utah 84107, United States
  • MultiCare Good Samaritan Hospital
    Tacoma, Washington 98405, United States
  • Kirk Barber Research
    Calgary, Alberta T2G 1B1, Canada
  • Beacon Dermatology
    Calgary, Alberta T3E 0B2, Canada
  • Alberta DermaSurgery Centre
    Edmonton, Alberta T6G 1C3, Canada
  • Dr. Chih-ho Hong Medical Inc.
    Surrey, British Columbia V3R 6A7, Canada
  • Enverus Medical Research
    Surrey, British Columbia V3V 0C6, Canada
  • Simcoderm Medical & Surgical Dermatology Centre
    Barrie, Ontario L4M 7G1, Canada
  • Kingsway Clinical Research
    Etobicoke, Ontario M8X 1Y9, Canada
  • Lynderm Research Inc.
    Markham, Ontario L3P1X2, Canada
  • Allergy Research Canada Inc.
    Niagara Falls, Ontario L2H 1H5, Canada
  • SKiN Centre for Dermatology
    Peterborough, Ontario K9J 5K2, Canada
  • The Centre for Dermatology
    Richmond Hill, Ontario L4B 1A5, Canada
  • York Dermatology Center
    Richmond Hill, Ontario L4C 9M7, Canada
  • Medicor Research Inc
    Sudbury, Ontario P3A 1W8, Canada
  • K. Papp Clinical Research
    Waterloo, Ontario N2J 1C4, Canada
  • XLR8 Medical Research
    Windsor, Ontario N8W 1E6, Canada
  • Innovaderm Research Inc
    Montreal, Quebec H2X 2V1, Canada
  • Centre de Recherche Dermatologique de Quebec Metropolitain
    Quebec, G1V 4X7, Canada
  • Dr. Samuel Sanchez PSC
    Caguas, 00727, Puerto Rico
  • Office of Dr. Alma M. Cruz
    Carolina, 00985, Puerto Rico
  • Ponce School of Medicine CAIMED Center
    Ponce, 00716, Puerto Rico
  • GCM Medical Group, PSC - Hato Rey Site
    San Juan, 00917, Puerto Rico
09

References and documents

Publications

  • King B, Maari C, Lain E, Silverberg JI, Issa M, Holzwarth K, Brinker D, Cardillo T, Nunes FP, Simpson EL. Extended Safety Analysis of Baricitinib 2 mg in Adult Patients with Atopic Dermatitis: An Integrated Analysis from Eight Randomized Clinical Trials. Am J Clin Dermatol. 2021 May;22(3):395-405. doi: 10.1007/s40257-021-00602-x. Epub 2021 Apr 7. PubMed 33826132 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.

Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2018 to primary completion in Oct 2021, 39 months.

Results were first posted in Nov 2022, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 6, 2018
First posted
Jun 18, 2018
StartActual
Jun 27, 2018
Primary completionActual
Oct 14, 2021
CompletionActual
Jun 13, 2022
Results first posted
Nov 8, 2022
Last update
Nov 8, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 8, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03559270
Collaborators
Incyte Corporation
Responsible party
Sponsor
First posted
Jun 18, 2018
Start date
Jun 27, 2018
Primary completion
Oct 14, 2021
Completion
Jun 13, 2022
Results posted
Nov 8, 2022
Last update
Nov 8, 2022

Study contacts

1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Oct 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Baricitinib

Start the discussion